The FDA announced a nationwide recall of over 140,000 bottles of a prescription cholesterol medication due to “failed ...

With an increasing number of available drugs along with a focus on early treatment regimens and drug sequencing in Crohn's disease, data from prospective, well designed studies to guide on drug choice ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting an observational cohort study titled ‘Treating ...

ITM-11 significantly improved PFS and OS in GEP-NET patients compared to everolimus, with a favorable safety profile and higher overall response rates. Dosimetry data showed targeted tumor uptake with ...

Now, it’s worth noting Stock Advisor’s total average return is 1,033% — a market-crushing outperformance compared to 193 % ...

Building on data showing radio’s edge in OTC advertising, Katz finds AM/FM drives double-digit awareness gains for a ...

Genmab A/S (NASDAQ: GMAB) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Ram Selvaraju ...

RVO Health’s Suzy Jackson joins us to talk about its new digital health division and what “direct-to-patient” really means for the patient experience.

Patients with advanced triple negative breast cancer ineligible for immunotherapy may overcome their typically poor prognosis with antibody-drug conjugates, suggest two trials presented at ESMO 2025.

Vertex should earn other important approvals through 2030 that could jolt its stock price. It's developing a treatment called ...

Pfizer's new COVID vaccine shows promising results with 4x immunity boost, but Kennedy's restrictions leave most Americans ...

Cigna will remove drug rebates from 2027, replacing them with upfront discounts that could change how Americans pay for ...